pharma

Sun Pharma

SUNPHARMA · Nifty 50

1,820.4

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

ValuationPE 37.9 (33%ile of 5Y range 31-48). Trading near median.
Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score80/100 (STRONG). 1 positive flags, 2 concerns.
Historical Context162 similar technical setups. Average outcome: -8.6% decline. 0% positive.
Revenue TrendRevenue growing at 12.8% YoY. Moderate revenue growth — 12.8% YoY

Fundamental

80/100

STRONG

Trust

95/100

Verification

Coverage

89/100

HIGH

Quick Take

Sun Pharma scores 80/100 on fundamentals (strong). Sun Pharma: PE below historical average. BROAD EXPANSION regime.

Fundamental Score: 80/100 · STRONG · 1 signals detected

DuPont Analysis

ROE 12.6% broken into three drivers. Each shows how efficiently the company generates returns.

ROE12.6%=
18.6%Net Margin
×
0.5xTurnover
×
1.3xLeverage

ROE of 12.58% is moderate margin-driven and stable. Net margin of 18.6% × asset turnover of 0.52x × leverage of 1.3x.

What This Means

Net margin of 18.6% means the company keeps ₹18.6 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.52x means the company efficiently uses its assets to generate revenue. Leverage of 1.3x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

80.2%

Operating

25.6%

Net

18.6%

declining

Gross margin 80.2% → operating margin 25.6% → net margin 18.6%. Margins are DECLINING. Check if input costs are rising or competition is pressuring pricing.

Financial Health

Earnings Quality

ADEQUATE

Cash flow covers net income 1.2x — earnings are ADEQUATE quality. Cash conversion is reasonable.

Debt Sustainability

COMFORTABLE

Interest covered 50.3x — very comfortable. Debt service is not a concern. Debt/EBITDA at 0.3x is low — balance sheet has capacity.

Free Cash Flow

MODERATE

FCF margin at 15.6% — strong cash generation. Business is self-funding.

Peer Comparison

Sun Pharma is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹1911 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹1729 (-5%)

Further downside risk

🟡

PE reverts to 5Y median of 37.9

Valuation normalization

🟢

Pharma sector entering leadership

Sector rotation signal

Detected Patterns

➡️ Leverage Slowly Rising: Debt growing faster (95.9%) than equity (15.7%)

Risk Flags

⚠️ 2 Warning1 Positive3 total flags
⚠️Special charges present in income statement
Earnings Quality

Special charges of ₹1307K Cr. May indicate restructuring, impairment, or one-time costs.

⚠️88% of debt is short-term
Balance Sheet

High refinancing risk. Company needs to roll over debt frequently. Vulnerable to credit market freezes.

High promoter holding: 56%
Governance

Strong insider alignment. Promoters have significant skin in the game.

➡️ 3 flags — 1 positive, 2 warning. Mixed profile.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
Our margin analysis (declining) matches news reports of cost/margin pressure

50 articles scanned for fundamental themes

Facts

P/E Ratio
37.9HIGH
P/B Ratio
5.2HIGH
ROE
14.7%HIGH
Market Cap
₹43372776.0L CrHIGH
From 52W High
95% of high
Promoter Holding
55.6%MODERATE
Institutional
31.4%
Sector Peers
10
Sun Pharma Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight